Magnesium Treatment in Hypoparathyroidism

• Register: ClinicalTrials.gov
• Last refreshed on: 19 February 2015
• Main ID: NCT00824226
• Date of registration: 15/01/2009
• Prospective Registration: No
• Primary sponsor: University of Tartu
• Public title: Magnesium Treatment in Hypoparathyroidism
• Scientific title: Effect of Magnesium Treatment on Plasma Calcium in Hypoparathyroid Patients
• Date of first enrolment: January 2009
• Target sample size: 10
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00824226
• Study type: Interventional
• Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
• Phase: N/A

Countries of recruitment

Estonia

Contacts

• Name: Vallo Volke, MD, PhD
• Affiliation: University of Tartu, Institute of Physiology

Key inclusion & exclusion criteria

Inclusion Criteria:

- primary or secondary hypoparathyroidism

- treatment with calcium plus vitamin D analogue

- ionized calcium 1,0-1,29 mmol/L

- magnesium level 0,7-1,05 mmol/L

- TSH 0.1- 10 imU/L

Exclusion Criteria:

- any other disease known to influence plasma Ca level

- pregnancy

- creatinine > 150 microM/L

- patient has used supplementary magnesium within 2 previous months



Age minimum: 18 Years
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

Hypoparathyroidism

Intervention(s)

Dietary Supplement: magnesium

Primary Outcome(s)

Calcium level at the end of magnesium treatment compared to pretreatment level [Time Frame: 3 weeks]

Secondary Outcome(s)

Calcium level after stopping treatment compared to the level at the end of magnesium treatment [Time Frame: 2 weeks]

Secondary ID(s)

UT296

Source(s) of Monetary Support

Please refer to primary and secondary sponsors